News
ARYX
0.0012
NaN%
--
Weekly Report: what happened at ARYX last week (0421-0425)?
Weekly Report · 2d ago
Weekly Report: what happened at ARYX last week (0414-0418)?
Weekly Report · 04/21 11:48
Weekly Report: what happened at ARYX last week (0407-0411)?
Weekly Report · 04/14 11:35
Weekly Report: what happened at ARYX last week (0331-0404)?
Weekly Report · 04/07 11:35
Weekly Report: what happened at ARYX last week (0324-0328)?
Weekly Report · 03/31 11:48
Weekly Report: what happened at ARYX last week (0317-0321)?
Weekly Report · 03/24 11:35
Weekly Report: what happened at ARYX last week (0310-0314)?
Weekly Report · 03/17 11:47
Weekly Report: what happened at ARYX last week (0303-0307)?
Weekly Report · 03/10 11:49
Weekly Report: what happened at ARYX last week (0224-0228)?
Weekly Report · 03/03 11:47
Weekly Report: what happened at ARYX last week (0217-0221)?
Weekly Report · 02/24 11:48
Weekly Report: what happened at ARYX last week (0210-0214)?
Weekly Report · 02/17 11:45
Weekly Report: what happened at ARYX last week (0203-0207)?
Weekly Report · 02/10 11:37
Weekly Report: what happened at ARYX last week (0127-0131)?
Weekly Report · 02/03 11:43
Weekly Report: what happened at ARYX last week (0120-0124)?
Weekly Report · 01/27 11:46
Weekly Report: what happened at ARYX last week (0113-0117)?
Weekly Report · 01/20 11:36
Weekly Report: what happened at ARYX last week (0106-0110)?
Weekly Report · 01/13 11:37
Weekly Report: what happened at ARYX last week (1230-0103)?
Weekly Report · 01/06 11:46
Weekly Report: what happened at ARYX last week (1223-1227)?
Weekly Report · 12/30/2024 11:39
Weekly Report: what happened at ARYX last week (1216-1220)?
Weekly Report · 12/23/2024 11:47
Weekly Report: what happened at ARYX last week (1209-1213)?
Weekly Report · 12/16/2024 11:48
More
Webull provides a variety of real-time ARYX stock news. You can receive the latest news about Aryx Therapeu through multiple platforms. This information may help you make smarter investment decisions.
About ARYX
ARYx Therapeutics, Inc. is a United States-based pharmaceutical Company. The Company is developing a proprietary portfolio of patient-targeted, first-in-class monoclonal antibodies designed to treat seriously ill patients with difficult-to-treat diseases. It is engaged in retrometabolic drug design that focuses on the safety of oral therapies for chronic disease. The Companys clinical compounds include naronapride (ATI-7505) for gastrointestinal disorders; budiodarone (ATI-2042, for the treatment of atrial fibrillation; tecarfarin (ATI-5923) for the treatment of anticoagulation; and ATI-9242, for psychiatric disorders.